Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
29.96
-1.48 (-4.71%)
At close: Nov 20, 2026, 4:00 PM EST
30.20
+0.24 (0.80%)
After-hours: Nov 20, 2026, 5:33 PM EST
Viridian Therapeutics Stock Forecast
Stock Price Forecast
According to 18 analysts polled by S&P Global, Viridian Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $42.76. The average 1-year stock price forecast is 42.72% higher than the current stock price, while the lowest is $33 (+10.15%) and the highest is $54 (+80.24%).
Price Target: $42.76 (+42.72%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 14 | 14 | 14 | 15 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 17 | 17 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Initiates $47 | Buy | Initiates | $47 | +56.88% | Nov 19, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $34 → $39 | Buy | Reiterates | $34 → $39 | +30.17% | Nov 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $40 | Buy | Maintains | $40 | +33.51% | Nov 9, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Reiterates $50 → $54 | Buy | Reiterates | $50 → $54 | +80.24% | Nov 5, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $26 → $33 | Buy | Maintains | $26 → $33 | +10.15% | Nov 5, 2026 |
Financial Forecast
Revenue This Year
76.22M
from 70.85M
Increased by 7.57%
Revenue Next Year
323.39M
from 76.22M
Increased by 324.31%
EPS This Year
-3.48
from -3.32
EPS Next Year
-2.07
from -3.48
EPS and Forward PE are based on non-GAAP adjusted numbers.